Progressive multifocal leukoencephalopathy (PML) is a deadly brain disease caused by the polyomavirus JC (JCV). The aim of this study is to develop 'designer T cells' armed with anti-JCV TCR-based chimeric immune receptors (CIRs) by gene modification for PML immunotherapy. Two T cell lines specific to two dominant CTL epitopes derived from JCV VP1 protein (termed p36 and p100) from an HLA-A0201 1 PML survivor were generated for TCR cloning. Two distinct dominant TCR alpha chains (Va6 and Va12) and a unique TCR beta chain (Vb5.1) were cloned from the p36-specific cell line, while only one alpha (Va8.6) and one beta (Vb2) chains were dominant in the p100-specific line. Retroviral constructs encoding CIRs were created with the extracellular domains of TCR a and b chains fused to the transmembrane and cytoplasmic portions of CD3z (VaCaCD3z or VbCbCD3z). Cellular expression and screening for binding specific peptide-HLA-A0201 tetramer confirmed the reactivity of the p100 TCRab and of one of the two pairs of p36 TCRab (Va12 and Vb5.1). Functional tests confirmed CIR-expressing T cells secreted cytokines and expressed potent cytotoxicity on contact with A0201 1 B-lymphoblastoid line loaded with peptides and/or with HLA-A0201 1 cells expressing native JCV VP1 protein. In conclusion, anti-JCV designer T cells were generated.
Introduction
Polyomavirus JC (JCV) is the etiologic agent of progressive multifocal leukoencephalopathy (PML), a lytic infection of oligodendrocytes associated with underlying immunosuppression or deficiency (1) . JCV infects 90% of normal adults (2), but does not cause disease in healthy individuals. Viral reactivation occurs in 5% of patients with acquired immunodeficiency syndrome (AIDS), which accounts for >80% of PML cases, and occasional other individuals who are profoundly immunosuppressed. This reactivation leads to a lytic infection of oligodendrocytes and an associated demyelination of the central nervous system. There is no effective treatment for PML, with a median survival of 11 months. The disease has become a growing medical problem that continues to occur in HIVinfected individuals despite the introduction of highly active antiretroviral therapy (HAART) regimens (3) . In addition, PML has recently been diagnosed in a few patients with multiple sclerosis and Crohn's disease treated with natalizumab, an immunomodulatory antibody that blocks integrin receptors (4, 5) .
A humoral immune response is inadequate to prevent reactivation of JCV and development of PML. However, previous studies demonstrated that the presence of JCV-specific CD8+ CTL was associated with long-term survival in HIV+ individuals with PML (6, 7) . Most of these CTL specificities have been identified with the JCV T or VP1 proteins that together account for two-thirds of the viral genome (7) . For example, cytolytic activity against cells expressing VP1 capsid protein could be identified in the blood of 10/11 HIV+ PML survivors but was absent in 10/11 PML progressors (8) . We (Koralnik et al.) previously characterized a panel of JCV peptides in the context of HLA A0201 (HLA A2 + ), the most common MHC class I allele, present in ;40% of all ethnic populations (9) . Two 9mer peptides, p36 (VP1 p36-44 : SITEVECFL) and p100 (VP1 p100-108 : ILM-WEAVTL), were found to be recognized by CTLs from PML survivors and the majority of healthy individuals, but not in patients with rapidly fatal outcomes (7, (10) (11) (12) .
Adoptive immunotherapy with ex vivo expanded autologous virus-specific CTL has been used successfully for the treatment of EBV and cytomegalovirus infections in immunosuppressed bone marrow transplant recipients (13, 14) . This suggests that if JCV-specific T cells could be created and similarly expanded and supplied to PML patients lacking these specificities, then a similar therapeutic outcome might also be obtained.
Our laboratory (Junghans et al.) has focused on the development and application of chimeric immune receptors (CIRs) to create so-called 'designer T cells' that are redirected to targets according to the conferred designed specificities (15) . Whereas most such applications have been with antibody-based CIRs, TCRs and TCR-based CIRs (TCRCIRs) and TCR-like antibody-based CIR for MHC class I-restricted antigens have been successfully created against a range of targets, both infectious [e.g. HIV gag/HLA-A3 (16) , HIV pol/HLA-B35 (17) , EBV LMP2/HLA-A2 (18) , EBV FLR/B8 (19) , and EBV IVT/A11EBNA/3A (19) ] and malignant (e.g., melanoma cancer/testis antigens (MAGE-1/HLA-A1) (20, 21) , melanocyte differentiation antigens [MART-1/HLA-A2 (22, 23) , gp100/HLA-A2 (24, 25) ]. These TCRs (16) (17) (18) (22) (23) (24) (25) , TCRCIRs (19, 20) and TCR-like antibody-based CIR (21) have been shown to redirect modified bulk human T cells to bind the relevant peptide/MHC ligands and also to activate normal T cell effector functions upon antigen presentation.
In the current study, we molecularly cloned two pairs of TCRab chains specific to the two dominant JC virus VP1-derived CTL epitopes (p36 and p100) from an HLA-A0201 + HIV+ PML survivor. TCRCIRs were created as fusion products of TCRa and TCRb with the zeta signaling chain of the CD3 complex. When the cognate ab pairs were coexpressed in human T cells by retroviral transduction, binding was confirmed for specific peptides of JCV VP1 in HLA-A2 + context, both by soluble MHC tetramer complexes and by naturally processed peptides on VP1-expressing target cells. These TCRCIR-modified designer T cells exhibited T cell activation and signaling with cytokine secretion in an antigen-specific manner. These new anti-JC virus designer T cells hold promise as the first specific agents for PML adoptive immunotherapy.
Materials and methods

Cell lines and antibodies
TCR-positive T cell line Jurkat, American Type Culture Collection, and an HLA-A0201
+ EBV-transformed B-lymphoblastoid line (B-LCL) were cultured in RPMI 1640 plus 10% heatinactivated FCS (R-10). The amphotropic and ecotropic retroviral packaging cell lines, Phoenix-amphotropic and Phoenix-ecotropic (gift of W. Pear, MIT, Boston), and the packaging cell line, PG13, were grown in R-10.
PE-or FITC-conjugated or unconjugated anti-human Vb2 (clone MPB2D5), Vb5.1 (clone IMMU157) and Vb20 (clone ELL1.4) antibodies were purchased from Immunotech (Beckman Coulter, Fullerton CA, USA). FITC-conjugated anti-human CD4 or CD8 antibodies were purchased from Caltag Laboratories (Invitrogen, Carlsbad CA, USA). Antihuman CD3 antibody (OKT3) was purchased from JOM Pharmaceutical (Somerset NJ, USA). JC virus-derived peptides, p36 (VP1 p36-44 : SITEVECFL) and p100 (VP1p 100-108 ILMWEAVTL), were synthesized with over 90-98% purity and purchased from Mimotopes (Victoria, Australia) or Invitrogen. PE-or APC-conjugated p36 or p100/HLA-A0201 tetramers were either prepared in the Koralnik lab or obtained from National Institutes of Health MHC Tetramer Core Facility (Atlanta GA, USA). APC-conjugated p36 or p100/HLA-A0201 pentamers were purchased from ProImmune (Bradenton, FL, USA).
Generation of T cell populations enriched for JC virus p36 or p100 reactivity PBMCs, obtained from an HIV+ PML patient with an inactive form of the disease, were separately stimulated with 1 lg/ml of p36 and p100 peptide for 10-14 days. The stimulated PBMCs were then stained with fluorochrome-labeled VP1 p100/A0201 tetramer and incubated with antifluorochrome immunomagnetic beads. Tetramer-stained cells were positively selected using an autoMACS cell sorter (Miltenyi Biotec). Sorted cells were then mixed at a ratio of 1:10 with autologous irradiated PBMC used as feeder cells in the presence of anti-CD3 antibody 12F6 at a concentration of 0.1 mg/ml. After two weeks of expansion in vitro in tissue culture medium containing 20 U IL2/ml, cells were subjected to another round of enrichment.
Molecular cloning p36 or p100/HLA-A0201-specific TCRs
To clone the a and b chain of TCRs specific to p36 or p100 HLA A0201, two specific reverse PCR primers were applied: TCRCaR (5#-CTGTCTTACAATCTTGCAGATCTCAGCTGGAC-C-3#) and TCRCbR (5#-TGAGGGCGGGCTGCTCCTTGAG-GGGCTGCG-3#). The nucleotide sequence of primer TCRCaR exactly matches the sequence encoding the C-terminus and stop codon of a chain. The sequence of primer TCRCbR matches a sequence near the middle of the constant region of both C1 and C2 allotypes. In combination with forward primers provided by a SMART RACE cDNA Amplification Kit (Clontech, Mountain View CA, USA), the expected PCR products are full-length cDNA for TCR a chain but partial cDNAs encoding VDJ and half of C for TCR b chain. Due to unexplained technical reasons, PCR primers designed to generate cDNA to include the full Cb did not yield valid results in PCR reactions. The full Cb was recovered during the subcloning into the retroviral expression vector (below).
Total RNA was extracted from a cell pool enriched with p36 or p100 HLA A0201 tetramer binding T cells after sorting for double Vb5.1 and JCVp36/HLA-A2 tetramer or Vb2 and JCVp100/HLA-A2 by FACS (Fig. 1) . The 5# RACE firststrand cDNA was synthesized using a SMART RACE cDNA amplification kit (Clontech) and then used as template for PCR reaction to amplify the desired cDNAs encoding TCR a and b chains in the presence of TCRa-specific primer TCRCaR and TCRCbR. The resultant specific TCR products with expected sizes were agarose gel purified and subcloned into the cloning vector. The sequences were selected for V(D)J-C usage identification using the BLAST2 algorithm and the ImMunoGeneTics database (http://imgt.cines.fr:8104/).
Construction of retroviral vectors encoding putative anti-JC virus CIRs
To identify and verify the functional binding pairs of anti-JC virus TCRs, and to study the signaling property of the CIRs, anti-JC virus TCRCIRs were created in two-chain two-vector (Tctv) format as previously described (20) . The cDNAs encoding VaCa or VbCb derived from our cloned five dominant TCR a and b chains (see Table 1 ) were linked as follows to the transmembrane domain (Tm) and cytoplasmic domain (Cy) of human CD3zeta (f) to generate TCRVaCaf and TCRVbCbf (Fig. 2 ) in MFG retrovirus (supplied by R. Mulligan, Harvard Medical School) modified to include a multi-cloning site (mcs).
To create VbCbf, vector was prepared first to encode Cb-f. A SwaI site (ATTTAAAT) was introduced in the sequence encoding amino acid residues of positions 2-4 (Asp-LeuAsn) in the N-terminus of the C1 region by making a few nucleotide mutations without causing any substitution of amino acid sequence. A DNA encoding Cb (C1) and the Tm and Cy of CD3f generated by PCR using pSTITCH vector plasmid DNA (20) as a template in combination with a pair of primers (Cb-F_XS: GACTCTCGAGATCGATTTAAATAAGGTG-TTCCCACCCGAGG and f_R_Stop_N: GTAATGCGGCCGC-AACTTAGCGAGGGGGCAG) was subcloned into XhoI/NotI sites of MCS region of the MFG-based retroviral vector to create an MFG-Cbf vector for subcloning purpose. The sites for XhoI (CTCGAG), SwaI (ATTTAAAT), NotI (GCGGCCGC) and stop codon (TTA) in the two primer sequences are underlined, respectively.
DNA fragments encoding VaCa, including the signal peptide sequence, derived from the three dominant cDNAs encoding TCR VaCa (p36Va6, p36Va12.2 and p100Va8.6) were amplified by PCR using specific primers: a common reverse primer that matches Ca region and 3# flanking sequence of BamHI site (GGATCC) (sequence: 5#-GTTTGGG-ATCCAGATCCCCACAGGAACTTTCTGGGC) and one of three specific forward primers with an XhoI site (CTCGAG) immediately upstream of the start codon (ATG) [(i) p36Va12.2_F: TCG-ACTCGAGAGCATGATGAAATCCTTGAGAGTTT; (ii) P36Va6_F: TCGACTCGAGAGCATGGAGTCATTCCTGGGAGG and (iii) p100Va8.6_F: TCGACTCGAGCCATGCTCCTGCTGCTCGTCC]. The PCR amplified cDNA encoding each of the 3 putative anti-JCV VaCa was subcloned into the XhoI/BamHI site, replacing the DNA encoding the Cb, in the cloning vector of MFG-Cbf to create VaCa f CIR (p36Va6f, p36Va12.2f and p100Va8.6f).
The cDNAs encoding the two dominant b chains (p36Vb5.1 and p100Vb2) were amplified by PCR with specific primers and inserted into the XhoI/SwaI site of the vector MFG-Cbf to create VbCbf CIR (p36Vb5.1Cbf and p100Vb2.1Cbf). The two pairs of specific forward and reverse primers used to amplify the Vb of p36Vb5.1 and p100Vb2 coding regions by PCR were as follows: for the p36Vb5.1 (p36Vb5.1_F: TCGACTCGAGACCATGGGCTC-CAGGCTGC and p36Vb5.1_R: AGTCCATTTAAATCCTCTAG-CACGGTGAGCC); for the p100Vb2 (p100Vb2_F: TCGA-CTCGAGAGCATGCTGCTGCTTCTGCTGCT and p100Vb2_R: AGTCCATTTAAATCCTCTACAACTGTGAGTC).
The start codon (ATG), XhoI site (CTCGAG) and SwaI site (ATTTAAAT) are underlined.
All vector inserts encoding CIRs were verified by DNA sequencing.
Vector-producer cell preparation
Phoenix cells (1:1 mixture of amphotropic and ecotropic) were transfected with 3 combinations of retroviral plasmids encoding possible pairs of putative functional anti-JCV TCR a and b chains (i.e. p36Va6Caf + p36Vb5.1Cbf, p36Va12Caf + p36Vb5.1Cbf or p100VaCaf + p100Vb2Cbf) and retroviral plasmid encoding p36Vb5.1Cbf alone as single b chain control. Viral supernatant of transfected Phoenix cells was used to infect helper PG13 cells to yield a Tctv vector producer cell (VPC) line. Infected PG13 cells were sorted first to enrich Vb-expressing cells by FACS sorting after staining with corresponding PE-labeled anti-Vb antibodies. The VPCs were re-infected with the same viral supernatant from Phoenix transfectants. The re-transduced PG13 cells were either directly subjected to FACS analysis for the CIR surface expression and peptide/A0201 tetramer-binding assay or further enriched for p36/A2 or p100/A2 tetramer-binding positive cells by FACS sorting for subsequent use as VPC for production of high titer retrovirus.
Cell transduction
Viral supernatant from PG13 VPCs was used to transduce Jurkat cells or primary human T cells (phTs) (PBMCs). The transduced Jurkat cells were later enriched for tetramerbinding cells by the same procedure as described for the PG13 cells (above).
Human PBMCs were activated with 50 ng/ml anti-CD3 antibodies (OKT3) in R-10 medium together with 360 IU/ml of recombinant human IL-2 (Chiron, Emeryville, CA, USA) for 2 days. The activated lymphocytes were then transduced with Tctv-p36f MFG retroviral vector using retronectin-coated plates as previously described (26), with modifications. Two runs of retroviral transduction were conducted in two consecutive days. Tissue-cultured 24-well plates were coated with recombinant retronectin (TaKaRa, Otsu, shiga Japan) at a concentration of 6 lg/cm 2 overnight at 4°C, blocked with 2% FCS in PBS and washed once with PBS. The plates were then pre-coated with retrovirus by adding 1 ml of viral supernatant to each well. The plate was spun at 2500 RPM (1049 3 g) in SORVALL RT-7 for 1 h at room temperature (R/T).
Post 2-to 3-day activated PBMCs (10 6 ) and 1 ml of prepared retroviral supernatant (containing 10 lg/ml protamine sulfate, 25 mM HEPES, and 36 IU/ml IL-2) were added to wells in the rectronectin-treated plate. The plates were spun at 2500 RPM for 1 h at R/T followed by incubation at 37°C 5% CO 2 atmosphere for 4 h before removing 750 ll of viral supernatant from each well and replacing with 1 ml of R-10 medium containing 360 IU/ml IL-2 and 25 mM HEPES. Next day, a second transduction was conducted in the same plate under the same conditions for the first transduction except that 1 ml of media was removed from each well and replaced with 1 ml freshly prepared retroviral supernatant. The transduced cells were then maintained at cell density of approximately 0.5 3 10 6 /ml in R-10 medium containing 360 IU/ml IL-2 and 25 mM HEPES. [In some instances, alternative but equivalent methods (26) were employed for supernatant production and modification of phTs.] These Tctv-p36f-transduced phT were used in tetramer-binding assays by FACS and cytokine secretion assays upon stimulation with JCV VP1 transduced melanoma cells.
Flow cytometry
Cells (2-5 3 10 5 ) were washed with R-10 medium and the cell pellets were re-suspended in 50 ll of R-10. Staining reagents (e.g., anti-TCR Vb antibodies, JCV peptide/A2 tetramer or pentamer) were added to the cell suspension for 20-30 min at R/T and then washed twice with PBS. The washed cell pellets were re-suspended in either PBS or PBS/2% paraformaldehyde before FACS on the same day. For experiments involving double staining with peptide/A2 tetramer or pentamer and anti-TCR Vb antibodies, the tetramer or pentamer was added to the cell samples 20 min before addition of anti-TCR Vb antibodies that were then incubated for another 20-30 min, without washing. FACS analysis was conducted with FACS Calibur or LSRII (Becton Dickinson, San Jose CA, USA). Only live cells were gated for the analysis.
Generation of JCV VP1-expressing cell line
An MFG-based polycistronic retroviral vector (MFG-IRES) was created by inserting an interual ribosome entry site (IRES) DNA sequence (derived from the pTandem-1 Vector, Novagen) into the MCS of MFG vector. The MFG-IRES vector was then used as a backbone to create a recombinant construct (VP1-IRES-GFP; VPIG) that consists of a cDNA encoding JCV VP1 protein of Mad-1 strain and a cDNA encoding an enhanced green fluorescent protein (GFP) (GenBank AN: AAB02572; Clontech) immediately upstream and downstream of the IRES by standard molecular cloning. The JCV VP1 cDNA in the plasmid termed 'PABT4587 JCV VP1' (7) was amplified by PCR and subcloned into the XhoI/NotI sites upstream of the IRES. A retroviral vector (IRES-GFP; IG), same as VPIG but without VP1 gene, was also constructed and used as negative control.
An HLA-A0201 + melanoma cell line (624.38, gift of M Dudley and S Rosenberg, Surgery Branch/NCI) was transduced with retroviral vectors encoding JC virus VP1 and GFP (VPIG) or GFP only (IG). The two resultant transduced melanoma cell lines, termed Mel38/VPIG (transduced with VPIG) and Mel38/IG (with IG), were selected to 90-98% GFP+ by cell sorting. The two cell lines were maintained in R-10 medium.
Cytokine secretion assays
Cytokine secretion assays were conducted by measuring IL-2 and IFNc concentrations in media harvested 24 h after coculture of CIR-expressing Jurkat or phT with an HLA-A0201+ B-LCL or JCV VP1+ Mel38 cells as APC in the absence or presence of a variety of stimuli. B-LCLs (10 6 ) were treated with mitomycin C (27) and then incubated with untransduced or CIR-transduced Jurkat cells (10 6 ) in flat-bottom 24-well plates in total volume of 1 ml of R-10 medium containing 10 ng/ml of PMA with or without various concentrations of the relevant peptides (0.1, 1 and 10 lg/ml), anti-TCR Vb antibodies (1 lg/ml) plus protein A (100 ng/ml), or ionomycin (500 ng/ml) for 24 h. For phT, 10 6 untransduced or CIRtransduced phT were incubated with or without 2 3 10 5 of mitomycin C-treated Mel38/IG or Mel38/VPIG in wells of flatbottom 24-well plates in total volume of 1 ml of R-10 medium with or without 2 lg/ml P36 peptide or plate-bound anti-OKT3 antibodies. (OKT3 was pre-coated to the wells by incubating 0.5 ml of 5 lg/ml in PBS overnight and then rinsing 3 times with PBS.) Supernatants from the cultures were harvested at 24 h and tested for IL-2 and IFNc concentrations using a human IL-2 ELISA kit (eBiosciences, San Diego CA, USA).
Cytotoxicity assays
For the killing assays, transduced T cells were first enriched by staining with p36/HLA-A2 or p100/HLA-A2 pentamers and then sorting on a FACS-Vantage instrument (BD). Sorted cells were then expanded in the presence of feeder cells of B-LCL with PHA (1 lg/ml). These enriched and expanded transduced T cells (90% modified) were used for cytotoxicity assays. The cytolytic activity of transduced human T lymphocytes was measured by 51 Cr release assays as described previously (20) . Peptide loading of B-LCL A0201 target cells was performed by adding VP1p36 or VP1p100 peptide at 10 lg/ml to the target cells 5-15 min prior to incubation with effector T lymphocytes at indicated ratios of effector to target cells. The incubation period of effector and target cells was 4 h. Percentage specific 51 Cr release was calculated as follows: [(test counts À spontaneous counts)/ (maximum counts À spontaneous counts)] 3 100%.
Results
Generation of T cell lines enriched for T cells expressing anti-JCV TCRs
PBMCs were isolated from an HIV+ PML patient in recovery from PML after initiating HAART therapy. Cells were stimulated in vitro first with JCV peptide p36 and p100 individually, then with anti-CD3 antibodies and enriched twice using p36/A2 or p100/A2 tetramer-positive binding cells. Two cell lines were generated: Line p36, enriched for JCV VP1p36 specificity, and Line p100, for JCV VP1p100 specificity. The purity of each enriched JCV-specific CTL population was assessed by tetramer staining. T cells were double stained with p36 or p100/HLA-A0201 tetramer and a panel of antihuman TCRb chain antibodies and subjected to FACS analysis. The double-positive (p36 or p100/HLA-A0201 tetramer and the most common Vb) cells were sorted for molecular cloning of TCRab. Nearly all JCV VP1p36-HLA-A0201-reactive T cells were Vb5.1, indicating the limited diversity of TCR repertoire against this peptide (Fig. 1) . In contrast, the most abundant Vb of the p100-reactive T cells, Vb2, accounted for less than one-third of the population (29%) (Fig. 1) . Double-positive cells were collected by FACS-based sorting. Selection of T cells expressing the most abundant Vb among the p100/HLA-A0201 tetramer-binding cells for TCR cloning was thought to select the most favored JCV-specific TCRs for cloning. Due to the lack of availability of antibodies specific to subsets of human TCR Va, only anti-human TCR Vb antibodies were employed in the current study.
Molecular cloning of anti-JCV TCRs
cDNAs encoding TCR a and b chains from the two enriched T cell populations with specificity to JCV p36 and p100 in the context of HLA-A0201 were amplified by PCR and cloned into TA cloning vector for subsequent DNA sequencing analysis. The cDNA sequences were subjected to analysis using the BLAST2 algorithm and the ImMunoGeneTics database (http://imgt.cines.fr:8104/) for V(D)J-C identification.
Clones for the p36-specific T cell line were examined. Among the 15 TCR a chain-related clones, 6 clones (40%) were identical with Va6J16 usage, while another 9 clones (60%) were identical with Va12.2J4 usage. In contrast, 22/ 22 cDNA clones (100%) for Vb were uniquely with Vb5.1J2 usage (the D usage was not clearly identified by this software) and with a type-2 constant region (C2).
From the p100-specific T cell line, 17/19 (90%) of clones encoding TCR a chain were identical with Va8.6J58 usage and 26/28 (93%) of clones encoding TCR b chain were with Vb20.1J1.1 and a C1 constant region.
Hence, two dominant a chains (V6J16 and V12.2J4) and a unique clonal b chain (V5.1J2) were cloned and identified from p36/HLA-A0201 selected T cells, while only one dominant a (V8.6J58) and one dominant b (V20.1J1.1) chain were identified from p100/HLA-A0201 selected T cells. The usages of both the dominant TCR b chains, Vb5.1 and Vb20.1, are consistent with the FACS data derived from specific anti-Vb staining for the T cell pools, from which the mRNAs were isolated. A summary of the TCR cloning results is shown in Table 1 .
[It is important to address a discrepancy in nomenclature of Vb2 and Vb20.1 as determined by the specificity of the antibody used for FACS staining as specified by the provider (anti-human Vb2 antibody; clone MPB2D5; Coulter) versus its identification by ImMunoGeneTics database analysis anti-human Vb2 monoclonal antibody (clone MPB2D5) from Coulter specifically recognizes TCR Vb20 based on IMGT's nomenclature, while anti-human Vb20 (clone ELL1.4) reacts with TCR Vb30. Subsequent studies showed that this dominant p100-TCR b chain was only recognized by anti-Vb2 antibody but not anti-Vb20 antibody (data not shown; also see below). For consistency, this particular TCR b chain will henceforth be referenced as Vb2 based on its reactivity with the commercial antibody that is used throughout this study.]
Preparing TCRCIR constructs
In order to test the functional pairs of the TCR a and b chains, chimeric TCRCIRs were created from DNA fragments encoding the dominant human TCR a and b chains with putative specificity to JCV p36 and p100 (Table 1) in an MFG-based retroviral vector. The DNAs encoding the extracellular portion of TCRVaCa or VbCb were linked to the Tm and Cy of human CD3f to create VaCaf or VbCbf (Fig. 2) . Five constructs were created.
Identification of functional pairs of native anti-JCV TCRs
Up to 30% of circulating human T cells may carry two TCR a chains of which only one is functionally reactive with peptide-MHC when paired with b chain (28) . We evaluated the TCRbinding activities to identify the functional pair of native anti-JCV TCRs derived from the p36 cell line and to confirm the functionality of sole pair of native anti-JCV TCR derived from the p100 cell line.
PG13 cells are derived from murine fibroblasts and are used to create VPC lines for retroviral production. The PG13 VPCs also serve as a cell model for identifying functional pairs of TCRs because transgene is expressed on the cell surface. PG13 cells were prepared with a and b pairs of anti-JCV p36 or p100 TCR (two pairs for p36 and one pair for p100) to create three VPC lines.
Each of the two a/b chain pairs for the p36TCRs of TCRVaCaf and TCRVbCbf was expressed on the PG13 cell surface as stained with anti-Vb5.1, but only the cells transduced by the combination of P36Va12 and P36Vb5.1 were able to bind p36/HLA-A2 tetramer (Fig. 3) . As expected, the dominant ab pair for the p100TCRs was functional by its ability to bind p36/HLA-A2 tetramer. Binding of JCV peptide/A0201 tetramer by the functional pairs of p36TCR (Va12 and Vb5.1) and p100TCR (Va8.6 and Vb2.1) was specific as no binding was observed with unrelated tetramer. Similar results were also obtained with APC-conjugated p36/A2 and APCp100/A2 pentamer (data not shown). In subsequent studies involving FACS analysis for JCV VP1 pep-A2 complex binding of cells, we used either tetramer or pentamer form. Due to the lack of availability of anti-human TCR a chain antibodies for flow cytometry analysis, the surface expression of a chain-CIR was not independently determined.
Human T cell lines expressing CIRs produced cytokine upon antigen stimulation
Having demonstrated that the anti-JCV CIRs specifically bind to their cognate peptide/MHC tetramers, we investigated whether the chimeric TCRs were also functional in terms of triggering activation of T cells. Jurkat human T cells were transduced with a combination of retroviruses encoding VaCaf and VbCbf to create Tctv-TCRCIR. After sorting for relevant peptide/A2 pentamer-positive cells, 80% of the resultant p36f-Jurkat cells and 59% of the p100f-Jurkat cells specifically bound to p36/A2 and p100/A2 pentamer, respectively, by FACS analysis (data not shown). The p36f-Jurkat cells secreted IL-2 at 12 and 24% of maximal when incubated with HLA-A0201+ B-LCL in the presence of p36 peptide at 1 and 10 lg/ml, respectively, as compared with stimulation with PMA + ionomycin (100%), but not in the presence of unrelated p100 (Fig. 4) . Similarly, Jurkat cells transduced with p100f produced IL-2 at 19 and 24% of maximal when incubated with HLA-A0201 + B-LCL in the presence of p100 peptide at 1 and 10 lg/ml, respectively, but not in the presence of unrelated p36 (Fig. 4) . These results for secreted IL-2 were compared with stimulations of the transduced Jurkat T cells with specific anti-TCR Vb antibodies. Jurkat/p36f secreted IL-2 when stimulated with antiVb5.1 antibodies (29%) but not with anti-Vb2 antibody, and Jurkat/p100f secreted IL-2 with anti-Vb2 antibody (38%) but not with anti-Vb5.1 antibody. These results indicate that these two anti-JCV CIRs with distinct antigen specificity are functional in inducing T cell activation upon stimulation with cognate antigen as peptide-MHC complex on cellular targets.
Anti-JC virus CIRs are functionally expressed on phTs
To investigate the functionality of anti-JC virus CIRs on phTs, we examined Tctv-CIR-transduced activated human T cells for activity: peptide/MHC I binding and antigen-induced cytokine secretion and cytotoxicity.
Tetramer binding.
After two runs of Tctv-p36f retroviral transduction, 22% of T cells were shown to express CIR on cell surface based CIR on anti-Vb5.1 antibody staining by FACS (Fig. 5) after subtraction of background of endogenous untransduced T cells expressing Vb5.1 (4%). There were 13% of transduced T cells that were doubly stained with p36/A2 pentamer and anti-Vb5.1 antibodies (Fig. 5) . The cells that are p36/A2 pentamer positive are inferred to co-express both a and b chains of the Tctv-p36f CIR (i.e., Tctv-p36VaCaf and Tctv-p36VbCbf). The fact that some transduced T cells are Vb5.1 positive but p36/pentamer negative (22 À 13 = 9%) indicates that these T cells are only transduced with the b chain CIR without co-transduction of the a chain CIR. In other phT transductions with p36 and p100 CIR, 15-60% of cells were pentamer positive (not shown).
We next investigated if co-expression of CD8 was essential to the tetramer binding on the transduced T cells. It was previously reported that CD8 was critical to stabilize this binding in other TCRs (29) (30) (31) or TCRCIRs (32) . In our case, transduced CD4 cells (Fig. 5F ) bound tetramer in equal fraction as transduced CD8 (Fig. 5D) (12 versus 13%) , confirming equal efficacy of infection across T cell subsets. Comparable intensities [mean fluorescence intensities (MFIs)] were observed (2192 versus 2758) between tetramer-bound CD8 (CD4 negative population) and CD4 cells based on analysis of cells in Fig. 5F , in which potential influence of anti-CD8 antibodies on tetramer binding was not an issue. We conclude that co-expression of CD8 is not important to the tetramer binding to our Tctv-p36f-transduced phTs.
IL-2 and IFNc release. To confirm that the TCRCIR format was functional in normal human T cells as it was in Jurkat, we then tested cytokine secretion with the modified p36-specific phT in Fig. 5 . For this test, T cells were stimulated with target cells expressing JCV VP1 protein from which p36 peptide is derived. VP1+ cell line, Mel38/VPIG and its negative control, VP1 negative Mel38/IG, were co-cultured with phT/Tctv-p36f or unmodified phT/NV, respectively. The secreted IL-2 and IFNc in the media harvested after 24-h co-culture were determined (Fig. 6 ). When stimulated with Mel38/VPIG and Mel38/VPIG plus p36 peptide, phT/Tctvp36f secreted IL-2 at 26 and 43% of maximal, respectively, versus anti-CD3 antibody stimulation as positive control (100%), but less than 0.5% was detected when stimulated with Mel38/IG or when cultured in media alone. phT/NV secreted high levels of IL-2 with anti-CD3 antibody stimulation, but not with other stimuli tested. When stimulated with Mel38/VPIG in the absence or presence of 2 lg/ml p36 peptide, phT/Tctv-p36f secreted 30 and 59% of maximal IFNc, respectively, versus anti-CD3 antibody stimulation (100%). A low level of IFNc (10%) was secreted by the phT/Tctv-p36f when co-cultured with VP1-negative Mel38/IG target cells. phT/NV only secreted IFNc with anti-CD3 antibody stimulation but not with other stimuli tested. (p100 CIR phTs were not similarly tested.)
Cytotoxicity assay. We finally tested for cytolytic activity of phTs transduced with functional Tctv-p36f and Tctv-p100f.
HLA-A0201
+ B-LCL cells loaded with cognate peptide of the two anti-JCV CIRs were used as target cells. The transduced phTs enriched for p36/HLA-A2 or p100/HLA-A2 specifically lysed target cells loaded with their cognate peptide VP1p36 or VP1p100 in the 51 Cr release assay (Fig. 7) . More than 85% killing was observed in 4 h when T cells expressing Tctv-p36f or Tctv-p100f were incubated with target cells loaded with cognate peptide at effector-to-target (E/T) ratio of 60:1. Even at the lowest ratio of 7.5:1, 35-55% of target cells were killed. These transduced T cells did not kill target cells unloaded with peptide or loaded with irrelevant peptide (<12% specific 51 Cr release).
Discussion
T cells genetically modified to express CIRs of desired antigen specificity (designer T cells) are a promising strategy for immunotherapy for cancer and infectious diseases (10 6 per well) were co-cultured with A2 + B-LCL (10 6 per well) in a 24-well plate in the presence of PMA (10 lg/ml) and each of various stimuli for 24 h and analysed for IL-2 production. Stimuli: JCV p36 or p100 peptide (0.1, 1 and 10 lg/ml), anti-TCR antibodies (anti-Vb5.1 antibody and anti-Vb2 antibody) (1 lg/ml) in the presence of protein A (100 ng/ml) to provide antibody cross-linking. IL-2 secretion by each cell line is expressed as percentage of maximum (100%) by PMA plus ionomycin: Tctv-p36f = 56.8 pg/ml and Tctv-p100f = 48.1 pg/ml. (13, 14, 23) . PML is a deadly brain disease caused by reactivation of JC virus in immune-depressed individuals, particularly in HIV+ subjects (1) . Currently, there is no effective therapy for this disease, with the sole option being to reverse immunodepression (5) . Even with HAART, half of PML patients die within 1 year after diagnosis (reviewed by Roberts) (33) .
CTLs that recognize two HLA-A0201-restricted CTL epitopes, p36 and p100, derived from JC virus capsid protein VP1 are present in HLA A0201+ PML patients who survive more than 1 year, but not in HLA A0201
+ patients with progressive disease who have a rapidly fatal outcome (8, 10, 11) . Furthermore, JCV VP1p36-or VP1p100-specific CTL was detected in the cerebrospinal fluid of 44% of patients with an inactive form of PML. These results indicate that JCV VP1-specific CTL can cross the blood-brain barrier and suggest that control of PML is not achieved by mere containment of JCV in the peripheral blood but also by lysis of JCV-infected oligodendrocytes in the white matter of the CNS (34) . Such an immune response could be also detected in 73% of healthy individuals, suggesting the CTLs specific to JCV may play an important role in preventing the development of PML in immunosuppressed individuals (12) .
Whereas the primary defect in AIDS is the deficiency in CD4 T cell number and function, CD8 T cells typically are ample. Antigen-specific CD4 T cells are important in dendritic cell activation that in turn select and activate CD8+ cells into becoming antigen-specific CTLs with cytotoxic effector functions (35) . CD4 cells also produce cytokines such as IL-2 that support CD8 T cell proliferation. To the extent that these CD4 functions can be substituted by gene therapy-conferred specificities and by ex vivo activation and in vivo cytokine support, the designer T cell strategy may have potential as an effective alternative therapy for PML in the absence of a functional CD4 subset. Cloning of TCRs with specificity to JC virus and engineering functional CIRs are prerequisites for preparing anti-JC virus designer T cells.
In the present study, we first generated two CTL cell populations from an HIV+ PML patient with specificity to the dominant p36 and p100 CTL epitopes derived from JC virus in the context of HLA-A2. This was accomplished by in vitro antigen stimulation and enrichment for antigen-specific TCRs and cell sorting. From the p100 CTL line, a unique TCRa and TCRb were cloned, and these were confirmed for functional binding. From the p36 specific line, however, two dominant a chains were cloned but only one b chain. In this case, only one a chain was functional when paired with the unique b chain. The fact that the cell population used for TCR cloning was sorted for p36/A2 tetramer-binding positive cells and nearly the same percentages of these two TCR a chains were cloned (Table 1) suggests that both a chains expressed concurrently at the single-cell level. It has previously been reported that up to 30% of human peripheral T cells express dual a chains of which only one is functional, when paired with b chain (28) . Particular advantages are conferred by the TCRf CIR format. CD3f is considered the limiting chain for assembly and cell surface expression of the TCR-CD3 complex, in which the polymorphic TCR ab chains associate with invariant chains (CD3c, CD3d, CD3e and CD3f) (36, 37) . In contrast to native foreign TCRab expressed in recipient T cells, the TCRf type CIRs bypass the limitation on surface expression by not having to compete with endogenous TCRab for CD3f to form TCR-CD3 complex. This notion is compatible with our findings of substantially higher surface expression (MFI) of TCRf CIRs compared with native TCR on transduced phTs (based on anti-Vb5.1 antibody staining; Fig. 5A and B) . 
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In addition, TCRf CIR avoids the problem of pairing of introduced TCRa/b of native form with endogenous a and b chains that will result in the dilution of the desired a/b pair. TCRCIR also avoids assembly of new TCRa/b heterodimers between endogenous and introduced TCRs that could theoretically result in unknown and possibly dangerous specificities without the benefit of thymic editing. The design of Tctv-TCRf CIRs precludes such illegitimate pairing to result in exclusively native pairing between the introduced TCR a and b chains (20) .
Although b chain in TCRCIR format can express solo on cell surfaces (data not shown), it was noted that all transduced phTs that co-express a chain (as evidenced by tetramer binding) also express higher levels of the b chain (Fig. 5B) . A similar observation of high expression in human T cells when co-transduced with a different Tctv-TCRf-based CIR specific to a melanoma antigen was previously reported by one of the authors (20) . It is speculated that co-transduction of the a chain of the Tctv-p36f CIR may enhance the stability of surface expressed b TCRf CIR in human T cells to result in the higher net expression of b.
In addition, we found that co-expression of CD8 did not enhance the tetramer binding to our Tctv-p36f-transduced phTs as measured by FACS (comparing CD4 and CD8 T cells; Fig. 5 ). When TCRs bind to cognate peptide-class I MHC, the CD8 co-receptor binds non-selectively to constant region of the MHC to stabilize the specific interaction. However, there are instances in which TCRs do not require CD8 binding that correlate with high native affinities of the TCRs for peptide-MHC that compensates for the lack of CD8 engagement (23, 31, 38) . One of the co-authors has reported that binding by a TCRab in a TCRf chimeric format to its cognate melanoma peptide-MHC complex is CD8 dependent (32) , while another TCRab in native form specific to a different melanoma antigen is not (39) . Our finding suggests that our Tctv-p36f-based TCRab possesses a high affinity for cognate peptide-MHC complex. Given that TCRf chimeras have either shown CD8 dependence (32) or CD8 independence (our case), it is likely that the topological effects contributed by the CIR format are not determining for the stability of the MHC-peptide-binding reaction. The same analysis was not performed for the p100 TCRCIR, but the fact that PG13 non-T cells that have no CD8 could express p100 TCRCIR and be detected for tetramer binding is compatible with this in vivo highly selected TCR also being of high affinity.
Finally, we demonstrate that phTs that were transduced with anti-JCV Tctv-p36f or Tctv-p100f could specifically lyse HLA-matched target cells presenting cognate peptide antigen (Fig. 7) , a key hallmark of CIR designer T cells for cellular immunotherapy.
To date, most work on designer T cells has been focused on cancer (15) . This effort extends this technology to an additional application in infectious diseases. This work shows the successful creation of TCRCIRs with specificity to JC viral antigens. When expressed in recipient human T cells, these TCRCIRs are shown to be functional in terms of redirecting phTs to recognize target cells presenting JCV antigens and to perform activation and signaling with cytokine production as well as cytotoxic activity. Products such as these may have clinical value in an immunotherapy strategy for PML. 
